Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Hoffmann-La Roche
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
Farmacocinética y seguridad de valganciclovir en pacientes pediátricos < 4 meses de edad, receptores de trasplante cardíaco. Pharmacokinetics and safety of valganciclovir in pediatric heart transplant recipients < 4 months of age
Definir la farmacocinética de ganciclovir tras la administración de valganciclovir polvo para solución oral en pacientes pediátricos <4 meses de edad receptores de trasplante cardíaco.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 5 ans
Étude CO39612 : étude de phase 1b-2 randomisée évaluant l’efficacité et la sécurité de plusieurs associations d’immunothérapies chez des patients ayant un cancer colorectal métastatique.
Le cancer colorectal est le deuxième cancer le plus fréquent chez la femme et le troisième chez l’homme. Il touche le côlon et le rectum et se développe lentement pendant 5 à 10 ans avant de s’étendre...
Country
France
organs
Côlon ou Rectum (colorectal)
Specialty
Immunothérapie - Vaccinothérapie
,
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A multiple ascending dose study to evaluate the safety, tolerability and effect on tumor response of the mTOR inhibitor (RAD001) in combination with the IGF-1R antagonist (R1507) in patients with advanced solid tumors
P Ib: • To characterize the safety and tolerability of R1507 administered every 3 weeks in combination with daily RAD001 and to determine the maximum-tolerated dose (MTD) of RAD001 administered orally...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A clinical study conducted at many clinical sites. In this study patients will be randomly assigned to one of two treatments. Neither staff at the site nor the patient nor the sponsor’s team will know if the patient received drug with an active ingredient or drug without an active ingredient. The goal is to see if the drug improves the progression of the disease in patients with systemic sclerosis and what the side effects are
•To assess the efficacy of treatment with TCZ 162 mg SC versus placebo SC given every week to patients with SSc, at Week 24 using the mRSS •To assess the safety of treatment with TCZ 162 mg SC versus...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A Phase III study to assess whether etrolizumab is a safe and effective treatment for patients with moderately to severely active Crohn's disease
Efficacy Objectives Induction Phase • To evaluate the efficacy of etrolizumab dose regimens compared with placebo in inducing CDAI remission, defined as a CDAI score < 150 at the end of the Inductio...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A Clinical Trial Evaluating the Addition of a Drug, Onartuzumab, to standard treatment (Erlotinib) in Patients with a Specific Generic Type of Lung Cancer
- To determine the efficacy of onartuzumab+erlotinib compared with placebo+erlotinib, as measured by progression-free survival (PFS) assessed by the investigator.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A multicenter, multinational phase II study to assess the clinical safety and feasibility of T-DM1 sequentially with anthracyline-based chemotherapy, as adjuvant or neoadjuvant therapy for patients with early stage HER2-positive breast cancer
To assess the clinical safety and feasibility of T-DM1 after the completion of doxorubicin/cyclophosphamide (AC) or 5-fluorouracil (5-FU)/epirubicin/ cyclophosphamide (FEC) adjuvant/neoadjuvant chemot...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F.Hoffmann-La Roche
Update Il y a 5 ans
A Phase II, Dose-Escalation to rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
To determine, in patients who do not develop any rash, or develop only grade 1 rash, within 4 weeks of start of treatment with gemcitabine + erlotinib, if overall survival can be improved by increasin...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 5 ans
GO28753 : Essai de phase 2 randomisé, comparant l’efficacité et la tolérance du MPDL3280A à celle du docétaxel comme deuxième ligne de traitement, chez des patients ayant un cancer du poumon non à petites cellules. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de comparer l’efficacité et la tolérance du MPDL3280A par rapport à celle du docétaxel, chez des patients ayant un cancer du poumon non à petites cellules en rechute après ...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
Estudio multicéntrico sobre la seguridad de oseltamivir administrado por vía intravenosa para el tratamiento de la gripe en pacientes de edad mayor o igual 13 años A Multicenter, Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged ?13 Years
Evaluar la seguridad del oseltamivir administrado mediante infusión intravenosa para el tratamiento de la gripe (estacional o causada por el virus pandémico [H1N1] 2009).
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
18
19
20
21
22
23
24
25
26
27
Next